Web Watch
Web Watch in One Page
Onyx Biotec is on Watchlist: the bear case carries the structural weight today (FY26 ROCE 1.14%, five-year cumulative free cash flow −₹32.35 Cr, IPO-era governance scaffolding), but the bull has a clean dated inflection in the H1 FY27 print due mid-November 2026 that resolves three of the four variables that matter. The stock sits at ₹32 — almost exactly book value of ₹30.6 — and the live debate is whether 1.05× book is a floor or a ceiling. The five active watches below were chosen to catch evidence that would change the 5-to-10-year view, not just anticipate the next print: the operating recovery test inside Onyx's own filings, the single multi-year thesis-changer (a regulated-market dossier at Unit II), the upstream competitive consolidation risk from Innova Captab's Kathua block, the long-promised but still-unmeasured Schedule M tailwind, and the most-likely modal failure mode (customer in-housing by the top-10 brand-owners that already run their own injectable lines).
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Onyx half-yearly results, annual report and material corporate filings | Daily | The H1 FY27 print (~13 Nov 2026) and the FY26 Annual Report (~Sep 2026) together resolve three of the four variables that matter — operating margin trajectory, debtor days, cash from operations sign — and for the first time disclose the receivables ageing schedule that decides whether the 1.05× book floor is real or whether stated book impairs from ₹30.6 to ₹22-26. | NSE/BSE board meeting outcomes, half-yearly or annual results with OPM, debtor days, CFO; first-ever trade receivables ageing schedule; top-5/top-10 customer concentration; audit committee composition or statutory auditor changes; LVP own-brand line commissioning; any provision for doubtful debts or qualified audit opinion. |
| 2 | Regulated-market accreditation (EU-GMP / USFDA / UK-MHRA) at Unit I or Unit II | Daily | The single multi-year thesis-changer. Driver #4 of the long-term underwriting map — every other variable (margins, working capital, ROCE) is downstream of whether Onyx ever signs the multi-crore capex cheque for a regulated-market dossier. The bull's FY2030 ₹85 fair value depends on this announcement; its absence through FY2028 is the strongest single refutation of the compounder case. | Any filing, inspection, capex commitment or first export shipment under EU-GMP, USFDA, UK-MHRA, ANVISA, PMDA or TGA at the Solan plant; multi-crore capex line tagged for a regulated-market dossier; first export contract or commercial invoice to a regulated market. |
| 3 | Innova Captab Kathua cephalosporin block utilisation and regulated-market wins | Daily | Innova's Kathua block — commissioned January 2025 at 23× Onyx revenue scale with EU-GMP credentials Onyx lacks, 30 km away in Baddi — sits upstream of any Schedule M displaced volume. If Innova fills Kathua above 70% with new EU/UK customer wins, the displaced cephalosporin pool consolidates upstream and Onyx's Unit II ramp ceiling drops from 70% to 50% independent of its own execution. | Innova Captab half-yearly or quarterly results, concall transcripts, investor presentations and press releases disclosing Kathua utilisation, new regulated-market customer wins, export revenue trajectory in sterile injectables, or any update on the Sharon Bio-Medicine integration. |
| 4 | CDSCO Schedule M enforcement and Solan/Baddi unit closures | Bi-weekly | The Schedule M deadline passed on 31 December 2025 but CDSCO has not yet published district-level closure data. The bull case has anchored on this tailwind for 18 months without a single observable number; a closure count above 200 named units in injectable categories validates the narrative, a count below 50 or a blanket retroactive extension kills one of the two pillars of the bull case. Also catches any inspection finding or WHO-GMP renewal observation at Onyx's own plant. | CDSCO or Himachal Pradesh State Drug Controller publication of Form A district-level closure counts; named exits of unlisted sterile injectable or cephalosporin manufacturers in Solan/Baddi; any retroactive extension or relaxation of Schedule M; any WHO-GMP / EU-GMP / USFDA inspection observation or 483-equivalent finding at the Onyx Solan plant. |
| 5 | Customer in-housing — top brand-owner captive injectable capacity additions | Bi-weekly | Failure mode #1: the most likely single cause of the FY26 operating margin collapse continuing into FY27-FY28. Top-10 customers were 71% of FY24 revenue and every name (Sun, Mankind, Hetero, Aristo, Macleods, Reliance Life Sciences) runs captive injectable capacity. Each captive-line capex announcement tightens the Unit I and Unit II ramp ceiling; tenure is not pricing power when the customer can self-supply at the margin. | Concall commentary, NSE/BSE filings, press releases or trade-press reports from Sun Pharma, Mankind, Hetero, Aristo, Macleods, Reliance Life Sciences, FDC, Zuventus or Akums disclosing new captive sterile injectable capacity, ampoule/vial/LVP lines, cephalosporin DPI expansion, lyophilised-vial or PFS capex, or any decision to in-house volume previously outsourced. |
Why These Five
The report's verdict frames the next twelve months as bear-with-a-trapdoor: the structural facts (ROCE 1.14%, cumulative five-year FCF of −₹32.35 Cr, governance scaffolding from the IPO window) argue the FY26 reset is not transient, while the H1 FY26 → H2 FY26 sequential OPM bounce from 2.72% to 7.02% keeps a clean dated inflection on the calendar. Monitor 1 is the cleanest catch for that inflection — the H1 FY27 print is the single dated catalyst inside six months and the FY26 Annual Report finally surfaces the receivables ageing detail that decides whether the 1.05× book floor is asset-bracketed or whether ₹52 Cr of "other current assets" carries a real-cash haircut of 15-25%. Monitor 2 is the only watch on this page whose payoff is asymmetric over a five-to-ten-year horizon: a regulated-market dossier filing is the single event that re-rates Onyx from a tangible-asset book-value name into a CDMO compounder candidate, and is the variable the verdict, the long-term thesis page and the moat page all flag as decisive. Monitor 3 tests whether the regulated-grade portion of the Schedule M displaced pool is being absorbed by Innova Kathua before it ever reaches Onyx — the most underweighted threat in the consensus bull case, with the resolution signal landing first (August 2026, ahead of the H1 FY27 print). Monitor 4 puts a quantifiable number on the long-promised Schedule M tailwind that has anchored the bull narrative for 18 months without observable evidence. Monitor 5 watches the modal failure mode — captive in-housing by the same top-10 brand-owners who are also Onyx's customers — and is the one watch that catches a slow-developing bear thesis breaker before it shows up in Onyx's own filings as a top-3 customer drop-out.